Prospects For OCs Market Opening In Japan Delayed

18 December 1995

Hopes of an early approval of oral contraceptives in Japan - where despite their availability in almost all countries of the world for nearly 30 years, they are still banned - appear to have been dashed by recent worries on the safety of several low-dose combination products (Marketletters passim).

Reform of Japanese legislation on OCs was expected after a Ministry of Health and Welfare advisory panel concluded that such products were both effective and safe, but then nothing happened. However, according to a report in the Financial Times, the 12 or so companies planning to launch their OC products in Japan when the law permitted, called for a meeting with the Ministry for clarification of the position, only to be told that no decision would be made until the latest safety data could be thoroughly evaluated.

To date, Japanese women have relied on abortion as a major means of birth control, with an estimated 400,000 pregnancy terminations a year. Given this, the FT suggests that gynecologists, reckoned to earn some 50 billion yen ($493 million) a year from performing abortions, have lobbied against reform.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight